
---
title: '当代狂犬病疫苗及不断优化的接种方案（1）'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://picsum.photos/400/300?random=9881'
author: 科学网
comments: false
date: Mon, 01 Nov 2021 13:59:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=9881'
---

<div>   
<p style="line-height: 200%"><strong><span style="font-family: Italic;line-height: 200%;font-size: 32px"><span style="font-family:Italic">当代狂犬病疫苗及不断优化的接种方案（</span>1）</span></strong></p><p style="line-height: 200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 24px;background: #FFFFFF"> </span></strong></p><p style="text-indent: 64px;line-height: 200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">本文主要取材于今年</span>6月出版的专业杂志《</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF">Viruses</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">》</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"> </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">上的一篇综述论文（见参考文献），原文的两位作者来自美国堪萨斯州立大学（曼哈顿），该大学是国际著名的狂犬病研究机构之一。该文的</span>3位审稿人分别是美国CDC主管狂犬病研究的现负责人和前负责人，以及美国农业部主管狂犬病问题的负责人。</span></strong></p><p style="text-indent: 64px;line-height: 200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">本文提供的权威资料可帮助公众更深入认识狂犬病和狂犬病疫苗：知道如何判断狂犬病疫苗的有效性，了解狂犬病疫苗接种方案不断优化的历程和未来发展趋势。</span></span></strong></p><p style="line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"> </span></p><p style="margin-left: 0;text-indent: 48px;line-height: 200%"><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 24px">摘要</span></strong></p><p style="margin-left: 0;text-indent: 40px;line-height: 200%"><span style="text-decoration: underline; font-family: "Palatino Linotype"; line-height: 200%; font-size: 20px;">细胞培养狂犬病疫苗（</span><strong><span style="text-decoration: underline; font-family: Bold; line-height: 200%; font-size: 20px;"> </span></strong><span style="text-decoration: underline; font-family: "Palatino Linotype"; line-height: 200%; font-size: 20px;">Cell culture rabies vaccines，CCV）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"><span style="font-family:Palatino Linotype">最早于</span>20世纪80年代获得批准，是预防人类狂犬病最重要的手段。</span><span style="text-decoration: underline; font-family: "Palatino Linotype"; line-height: 200%; font-size: 20px;"><span style="font-family:Palatino Linotype">世界卫生组织</span>(WHO</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">)推荐的第一个</span><span style="text-decoration: underline; font-family: "Palatino Linotype"; line-height: 200%; font-size: 20px;">暴露<span style="font-family:Palatino Linotype">后预防</span>(PEP)</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">疫苗接种方案是在总共长达三个月的时间内多次进行<span style="font-family:Palatino Linotype">肌肉注射。为了在不影响安全性的情况下降低</span>PEP的成本，WHO鼓励对两种策略进一步进行<span style="font-family:Palatino Linotype">研究，包括开发成本更低的</span> CCV生产方法和通过</span><span style="font-family: "Palatino Linotype"; line-height: 200%; font-size: 20px; text-decoration: underline;">皮内(ID</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">)途径接种剂量<span style="font-family:Palatino Linotype">更小的</span> CCV。大量临床试验提供了足够的数据，支持减少剂量、<span style="font-family:Palatino Linotype">缩短</span>PEP所需时间、<span style="font-family:Palatino Linotype">批准</span>PEP和</span><span style="font-family: "Palatino Linotype"; line-height: 200%; font-size: 20px; text-decoration: underline;">暴露前预防(PreP</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">)采用皮内接种途径。</span></p><p style="margin-left: 0;text-indent: 40px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"><span style="font-family:Palatino Linotype">然而，自</span>CCV开发</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">成功</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">以来公布的</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">海量</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"><span style="font-family:Palatino Linotype">数据可能会让公共卫生官员无法审查和决定其所在地区最合适的</span>PEP和PreP方案。本</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">综述</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">中，审查了三个关键</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">基准</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">（</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">benchmarks</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"><span style="font-family:Palatino Linotype">，可作为卫生官员在审查其所在地区实施新的</span>PEP和PreP方案的数据时的指导，包括接种后免疫原性的证据、对疾病发展有效的证明，以及正在考虑的方案得到确认后，<span style="font-family: "Palatino Linotype"; font-size: 20px; text-indent: 40px;">疫苗</span>加强接种后会引起迅速的</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">记忆</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">反应。</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">这些资料也可帮助公众深入认识狂犬病和狂犬病疫苗：知道如何判断狂犬病疫苗的有效性，了解狂犬病疫苗接种方案不断优化的历程和未来发展趋势。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 21px"><span style="font-family:Palatino Linotype">关键词</span>:</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 21px"> </span></strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"><span style="font-family:Palatino Linotype">狂犬病；</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">暴露</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">后预防</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">（</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">PEP</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">；</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">暴露前预防（</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"> PreP</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">；免疫原性</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">（</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">immunogenicity</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">；</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">效力（</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">efficacy</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">；记忆反应</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">（</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">anamnestic response</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">）。</span></p><p style="margin-left: 0;text-indent: 40px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"> </span></p><p style="margin-left: 0;text-indent: 48px;line-height: 200%"><span style="font-family: Bold;font-weight: bold;font-size: 24px">1. </span><strong><span style="font-family: Bold;line-height: 200%;font-size: 24px">概述</span></strong></p><p style="margin-left: 0;text-indent: 40px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"><span style="font-family:Palatino Linotype">狂犬病是一种人畜共患疾病，高达</span>99%的人类狂犬病死亡是因暴露于受感染的狗。因此，</span><strong><span style="color: #0070C0; font-family: "Palatino Linotype"; line-height: 200%; font-size: 20px;">预防大多数人类狂犬病病例的最有效的全球战略是在传染源，即在犬类中消除狂犬病的传播。</span></strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">在犬类狂犬病流行国家的几个成功的大规模犬类疫苗接种项目已经证明，消除犬类狂犬病是可行的，而且在预防人类狂犬病死亡方面具有成本效益。然而，在全球消除狂犬病之前，改善狂犬病流行国家获得人类狂犬病疫苗的机会是减少目前人类狂犬病死亡人数的关键。事实上，在暴露于患狂犬病的动物后，注射人用狂犬病疫苗以及适当的伤口护理被认为是预防人狂犬病的第一道防线。</span></p><p style="margin-left: 0;text-indent: 40px;line-height: 200%"><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #0070C0;font-size: 20px"><span style="font-family:Palatino Linotype">绝大多数种类的疫苗都必须在暴露于病原体之前接种才有效，而</span></span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #0070C0;font-size: 20px"><span style="font-family:Palatino Linotype">细胞培养狂犬病疫苗</span>(CCV</span></span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #0070C0;font-size: 20px">)是少数几种在暴露于病原体后</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #0070C0;font-size: 20px">才接种仍</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #0070C0;font-size: 20px">可以预防疾病的人类疫苗之一。</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #FF0000;font-size: 20px"><span style="font-family:Palatino Linotype">暴露后预防</span>(PEP)，包括在特定时期内给予多剂量疫苗，在预防狂犬病方面是如此成功，以至于在狂犬病流行地区没有必要为整个人群进行</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #FF0000;font-size: 20px">暴露前</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #FF0000;font-size: 20px">预防接种。</span></strong></p><p style="margin-left: 0;text-indent: 40px;line-height: 200%"><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">40多年前开发的CCV<span style="font-family:Palatino Linotype">是迄今为止开发的最有效的人类疫苗之一，并改变了公共卫生官员创建和实施人类狂犬病预防项目的方式。</span></span></strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"><span style="font-family:Palatino Linotype">目前使用最广泛的</span>CCV是在三种类型的细胞中产生的，包括:人类二倍体细胞，vero细胞和鸡胚细胞。在本文发表时，有4个CCV达到了</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">WHO</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">资格预审</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">（</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">prequalification</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">）</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">标准。</span><span style="font-family: "Palatino Linotype"; font-size: 20px;"> </span></p><p style="margin-left: 0;text-indent: 40px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">对人用狂犬病疫苗的建议必然因国家而异。例如，一个国家可能已经确定使用</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">皮内（</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">ID</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">）接种</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">方式是有益的，而另一个国家则没有。对已发表文献的回顾显示，已经进行了许多临床试验来评估各种方案中的</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">肌肉内（</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">IM</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"><span style="font-family:Palatino Linotype">和</span>ID</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">接种</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">途径。然而，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">海</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"><span style="font-family:Palatino Linotype">量已发表的与</span>IM和ID</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">接种</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">途径相关的数据</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">使得在试图改变用于人类狂犬病预防的国家狂犬病疫苗接种方案时很难对这些数据进行比较。</span></p><p style="margin-left: 0;text-indent: 40px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">本文简要回顾了当有必要比较</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"><span style="font-family:Palatino Linotype">用</span>CCV进行</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"> IM和ID</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">接种</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">的临床数据时，评估过程中应包括的三个关键因素。这三个关键因素</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"><span style="font-family:Palatino Linotype">是：</span>1）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">疫苗接种后存在</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"><span style="font-family:Palatino Linotype">狂犬病毒中和抗体</span>(RVNAs</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">)的证据，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">2）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">所考虑的方案可保护暴露于确诊狂犬</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">病</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">动物的患者的证据，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">3）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px"><span style="font-family:Palatino Linotype">已接受暴露前预防</span>(PreP)的人对疫苗加强</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">针</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">产生记忆反应的证</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">据</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">。</span></p><p style="margin-left: 0;text-indent: 40px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">（</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 24px">未完待续</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 20px">）</span></p><p style="line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 24px">参考文献：</span></p><p style="line-height: 200%;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">Briggs, D.J.; Moore, S.M. </span><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">The Route of Administration of Rabies Vaccines: Comparing the Data. </span></strong><strong><em><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">Viruses</span></em></strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"> 2021, 13, 1252.</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"> </span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"> <a href="https://www.mdpi.com/1999-4915/13/7/1252" target="_blank">https://www.mdpi.com/1999-4915/13/7/1252</a>  </span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"> </span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-347754-1310423.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-347754-1310423.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1310206.html" target="_black">在武汉刺鳗中发现B型流感病毒，祸兮福兮？</a><br>下一篇：<a href="http://blog.sciencenet.cn/blog-347754-1310513.html" target="_black">当代狂犬病疫苗及不断优化的接种方案（2）</a>                    <!--大赛结束-->
                                        
  
</div>
            